secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2021-09-27T23:59:59+00:00
Accession:  0001564590-21-048961
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta to initiate pivotal Part B of MOMENTUM study for SRP-5051 in DMD patients
--------------------------------------------------------------------------------

- Positive FDA interactions enable early start of Part B of MOMENTUM study for SRP-5051.
- Part B expected to serve as pivotal study seeking accelerated approval for exon 51 skipping DMD patients.
- Study will enroll 20-40 patients, ages 7-21, both ambulatory and non-ambulatory.
- Company anticipates initiating Part B in Q4 2021; protocol submission next week.
- SRP-5051 is a next-generation PPMO therapy; prior Part A data suggested efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000156459021048961/0001564590-21-048961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000156459021048961/srpt-8k_20210927.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-048961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer